Ir direto para menu de acessibilidade.
Página inicial > Recomendation Reports
Início do conteúdo da página

Recomendation Reports

Publicado: Sexta, 11 de Setembro de 2020, 18h48 | Última atualização em Quinta, 25 de Fevereiro de 2021, 12h00 | Acessos: 1230

Find below the Health Technology Assessment Reports developed by Conitec. 

Year/MonthTechnologyHTA Report
541 2020/June Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) for the first-line treatment of advanced (unresectable and metastatic) melanoma
539 2020/June Sirolimus Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis
538 2020/June Tofacitinib Citrate (Xeljanz®) Tofacitinib citrate for the treatment of moderate to severe ulcerative colitis in adult patients with inadequate response, loss of response or intolerance to previous treatment with conventional synthetic or biological drugs
 531  2020/June  Ruxolitinib (Jakavi®) Ruxolitinib for the treatment of patients with primary myelofibrosis, postpolycythaemia vera myelofibrosis or postessential thrombocythaemia myelofibrosis, in people with intermediate-2 or high-risk disease
526 2020/June Rifapentine plus isoniazid (3HP regimen) Rifapentine plus isoniazid for treatment of Latent Mycobacterium Tuberculosis Infection (LTBI)
525 2020/June Rifampicin 300 mg capsule, and 20 mg/mL oral suspension Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease
524  2020/March Empagliflozin and Dapagliflozin Empagliflozin and Dapagliflozin for the treatment of Type 2 Diabetes Mellitus
523  2020/March Orlistat Orlistat for weight loss in overweight or obese patients
522  2020/March Sibutramine Sibutramine for the treatment of obese patients
519  2020/March Riociguat Riociguat for inoperable or persistent/recurrent after surgical treatment Chronic Thromboembolic Pulmonary Hypertension
518 2020/April Treatment of Pseudomyxoma Peritonei Cytoreductive surgery (peritonectomy) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
517 2020/April Cytoreductive surgery (peritonectomy) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive surgery with hyperthermic chemotherapy in patients with malignant peritoneal mesothelioma
516 2020/March Newborn Screening Newborn Screening for Congenital Toxoplasmosis
515 2020/March Dolutegravir Dolutegravir for the treatment of pregnant women living with HIV
510 2020/March Baricitinib (Olumiant®) Baricitinib (Olumiant®) for patients with moderate to severe Active Rheumatoid Arthritis
509 2020/March Mirabegron Mirabegron for the treatment of storage dysfunction in patients with Neurogenic Bladder
508 2020/March  Oxybutynin, Tolterodine, Solifenacin and Darifenacin Antimuscarinics (Oxybutynin, Tolterodine, Solifenacin and Darifenacin) for the treatment of Storage Dysfunction in patients with Neurogenic Bladder
507 2020/March Photodynamic Therapy Photodynamic Therapy for non-melanoma skin câncer
506 2020/February Personal Frequency Modulation System Personal frequency modulation system for hearing-impaired students at any age and at any academic level
503 2020/January Testing for prothrombin gene mutation (G202110A), protein C functional assay, protein S functional assay, anti-beta2-glycoprotein I - IgG, lupus anticoagulant Diagnostic tests for thrombophilia in pregnancy
Fim do conteúdo da página